Literature DB >> 8859003

Effects of dopamine antagonists on neuronal histamine release in the striatum of rats subjected to acute and chronic treatments with methamphetamine.

C Ito1, K Onodera, E Sakurai, M Sato, T Watanabe.   

Abstract

In this study, we examined the changes in neuronal histamine (HA) release in the rat striatum after acute and repeated administration of methamphetamine (METH). We studied the regulation of METH-induced HA release by dopamine receptors and the relationship between METH-induced HA release and stereotyped behavior. Acute administration of METH (1 mg/kg) significantly increased HA release 60 min later. Pretreatments with the dopamine D2 antagonists sulpiride and haloperidol blocked the METH-induced increase of HA release, whereas pretreatment with a dopamine D1 antagonist, SCH23390, did not. Moreover, repeated administration of METH (3 mg/kg) greatly enhanced the METH-induced increase of HA release 60, 80, 100, 120 and 180 min after rechallenge of METH (1 mg/kg). Repeated treatment with haloperidol and METH blocked the increase of HA release induced by the rechallenge of METH. The METH-induced increase of HA release was still found after the METH-induced stereotyped behavior decreased in both acute and repeated administrations of METH. These findings suggest that the METH-induced HA release in the striatum is controlled by dopamine D2 receptors and may play an important inhibitory role in the METH-induced stereotyped behavior. Furthermore, a persistent change in the HA neuron system through DA neurotransmission may be partially responsible for the METH-induced behavioral sensitization.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8859003

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

1.  Proceedings of the 10th Asian Pacific Congress of Clinical Biochemistry in conjunction with the Australasian Association of Clinical Biochemists' 42nd Annual Scientific Conference.

Authors: 
Journal:  Clin Biochem Rev       Date:  2004

2.  Modulation of prepulse inhibition and stereotypies in rodents: no evidence for antipsychotic-like properties of histamine H3-receptor inverse agonists.

Authors:  Aude Burban; Chit Sadakhom; Dominique Dumoulin; Christiane Rose; Gwenaëlle Le Pen; Henriette Frances; Jean-Michel Arrang
Journal:  Psychopharmacology (Berl)       Date:  2010-05-01       Impact factor: 4.530

3.  Ontogenetic serotoninergic lesioning alters histaminergic activity in rats in adulthood.

Authors:  Jadwiga Jośko; Jacek Drab; Jerzy Jochem; Przemysław Nowak; Ryszard Szkilnik; Eva Korossy-Mruk; Dariusz Boroń; Richard M Kostrzewa; Halina Brus; Ryszard Brus
Journal:  Neurotox Res       Date:  2010-09-14       Impact factor: 3.911

4.  Histamine depolarizes cholinergic interneurones in the rat striatum via a H(1)-receptor mediated action.

Authors:  M I Bell; P J Richardson; K Lee
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

5.  Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, potentiates neurochemical and behavioral effects of haloperidol in the rat.

Authors:  Catherine Pillot; Jordi Ortiz; Anne Héron; Sophie Ridray; Jean-Charles Schwartz; Jean-Michel Arrang
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

6.  Effects of histamine H(3) receptor activation on the behavioral-stimulant effects of methamphetamine and cocaine in mice and squirrel monkeys.

Authors:  Matthew L Banks; Daniel F Manvich; Rayna M Bauzo; Leonard L Howell
Journal:  Pharmacology       Date:  2009-01-15       Impact factor: 2.547

7.  Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040.

Authors:  Eric Southam; Jackie Cilia; Jane E Gartlon; Marie L Woolley; Laurent P Lacroix; Carol A Jennings; Jane E Cluderay; Charlie Reavill; Claire Rourke; David M Wilson; Lee A Dawson; Andrew D Medhurst; Declan N C Jones
Journal:  Psychopharmacology (Berl)       Date:  2008-09-03       Impact factor: 4.530

8.  Histaminergic activity in a rodent model of Parkinson's disease.

Authors:  Przemysław Nowak; Lukasz Noras; Jerzy Jochem; Ryszard Szkilnik; Halina Brus; Eva Körossy; Jacek Drab; Richard M Kostrzewa; Ryszard Brus
Journal:  Neurotox Res       Date:  2009-02-28       Impact factor: 3.911

9.  CSF histamine levels in rats reflect the central histamine neurotransmission.

Authors:  Atsushi Soya; You Hwi Song; Tohru Kodama; Yoshiko Honda; Nobuhiro Fujiki; Seiji Nishino
Journal:  Neurosci Lett       Date:  2007-11-06       Impact factor: 3.046

10.  Inflammatory Animal Model for Parkinson's Disease: The Intranigral Injection of LPS Induced the Inflammatory Process along with the Selective Degeneration of Nigrostriatal Dopaminergic Neurons.

Authors:  A Machado; A J Herrera; J L Venero; M Santiago; R M de Pablos; R F Villarán; A M Espinosa-Oliva; S Argüelles; M Sarmiento; M J Delgado-Cortés; R Mauriño; J Cano
Journal:  ISRN Neurol       Date:  2011-04-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.